首页> 外国专利> METHOD FOR COMBINED TREATMENT OF NEOVASCULAR GLAUCOMA ACCOMPANYING DIABETIC OR POSTTHROMBOTIC MACULAR EDEMA IN PATIENTS WITH RESIDUAL VISION

METHOD FOR COMBINED TREATMENT OF NEOVASCULAR GLAUCOMA ACCOMPANYING DIABETIC OR POSTTHROMBOTIC MACULAR EDEMA IN PATIENTS WITH RESIDUAL VISION

机译:合并残留性视力合并糖尿病或血栓后黄斑水肿伴发性血管性青光眼的综合治疗方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, specifically to ophthalmology. For treating neovascular glaucoma accompanying the diabetic or postthrombotic macular edema in the patients with residual vision, ophthalmic examination and optical coherence tomography are performed to detect macular edema, localization and height. If observing the iris and / or angle of the anterior chamber, as well as the parameters of increased intraocular pressure, the treatment is performed, the first step of which is the introduction of a VEGF inhibitor. In 2 weeks after the first stage of treatment, the second stage of treatment is performed - transscleral cyclophotocoagulation of the ciliary body. In 2–3 weeks, panretinal laser coagulation of retina in ischemic zones is performed. If observing normal values of intraocular pressure by the second stage of treatment, panretinal laser coagulation of the retina in ischemic zones is performed.;EFFECT: method provides higher clinical effectiveness and safety, preserves residual visual functions and reduces the risk of intra- and postoperative complications.;1 cl, 2 ex
机译:技术领域本发明涉及医学,尤其涉及眼科。为了治疗伴有残留视力的糖尿病或血栓后黄斑水肿伴发的新生血管性青光眼,需进行眼科检查和光学相干断层扫描以检测黄斑水肿,局部和高度。如果观察前房的虹膜和/或角度,以及眼内压升高的参数,则进行治疗,其第一步是引入VEGF抑制剂。在第一阶段的治疗后2周内,进行第二阶段的治疗-睫状体的巩膜环光凝术。在2-3周内,对缺血区域的视网膜进行全视网膜激光凝结。如果在治疗的第二阶段观察到眼内压的正常值,则在缺血区域进行视网膜全视网膜激光凝结。;效果:该方法可提供更高的临床有效性和安全性,保留残余的视觉功能,并降低术中和术后的风险并发症。; 1 cl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号